Business Context and Reporting Period
Company: The Clorox Company (CLX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2019
Event: Entry into a new material definitive credit agreement and termination of a prior agreement.
Key Financial Metrics and Liquidity
This filing details a refinancing transaction rather than operational financial results. Key metrics include:
- New Credit Facility: $1.2 billion five-year unsecured revolving credit agreement.
- Prior Facility Terminated: $1.1 billion credit agreement (originally dated February 8, 2017).
- Termination Costs: No material termination fees or penalties were incurred.
- Financial Covenant: The new agreement contains only one financial covenant: a consolidated interest coverage ratio.
- Interest Rate Structure: Borrowings may be based on a Base Rate (Prime, Federal Funds, or LIBOR + 1%) or LIBOR, plus an applicable margin based on the Company's credit rating.
Material Changes Versus Prior Period
The primary material change is the replacement of the Company's existing credit facility:
- Capacity Increase: The new facility increases available liquidity by $100 million compared to the terminated $1.1 billion facility.
- Maturity Extension: The new agreement extends the maturity date to November 2024 (five years from execution), whereas the prior facility was set to mature on February 8, 2022.
- Lender Composition: The administrative agents remain JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association.
Outlook, Risks, and Management Commentary
Management Commentary: The Company entered the agreement for general corporate purposes. The filing notes that certain lenders have pre-existing relationships with the Company, including participation in prior credit facilities, share repurchase programs, and bond offerings.
Risks and Contingencies: The agreement includes customary events of default, including nonpayment, covenant defaults, bankruptcy, insolvency, cross defaults, and change of control. It also imposes customary negative covenants restricting liens, consolidations, mergers, and asset sales.
Unusual Items: The filing does not disclose any unusual items or non-recurring charges related to this transaction.
Important Facts for Investor Verification
- Verify the specific terms of the "consolidated interest coverage ratio" covenant in the attached Exhibit 10.1 to understand the threshold for compliance.
- Confirm the current credit rating of The Clorox Company to determine the applicable interest rate margin and facility fee under the new agreement.
- Review the Company's subsequent 10-Q or 10-K filings to determine if any amounts were drawn against the new $1.2 billion facility.
- Check for any changes in the Company's overall debt structure or leverage ratios resulting from this refinancing in future quarterly reports.